This document provides methods and materials for using umbilical cord blood to treat non-malignant disorders. For example, methods and materials for administering umbilical cord blood to a mammal (e.g., a human) via multiple (e.g., two or more) infusions to treat non-malignant diseases such as inherited disorders of metabolism, immunity, and/or hematopoiesis are provided.

A method of treating systemic sclerosis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

To develop a universal and long-lasting influenza or other pathogens vaccine has been a mission impossible goal in the life science and health field. Applicants disclose, herein, vaccines prepared against SARS-COV-2, an influenza A strain vaccine prepared from a 1934 influenza virus (A/PR/8/34 H1N1, Puerto Roca, 1934), and an influenza B strain vaccine prepared from a 1940 influenza virus. The disclosed vaccine induces production of broadly neutralizing antibodies in mice. The presently disclosed vaccine is able to inhibit two other influenza A strains: a 2009 influenza H1N1 virus collected from Los Angeles (A/California/07/2009) and a 2014 influenza H3N2 virus collected from Hong Kong (A/Hongkong/4801/2014). Applicants also describe an influenza B strain vaccine prepared from a B strain virus from a 1940 patient in USA (B/L11/40). The B strain vaccine also produced broadly neutralizing antibodies, in this case against a B strain from Colorado 2017 (B/Colorado/2017). Applicant's methods and compositions are not only useful in creating influenza vaccines with broad activity against other influenza subtypes but also be efficient to generate long-lasting SARS-CoV-2 vaccines against emerging new variants either through recombined protein antigens from SARS-CoV-2 or inactivated SARS-CoV-2 virus.

The present invention relates i. a. to an immunogenic composition comprising: a) one or more antigens of avibacterium paragallinarum and one or more antigens of avian encephalomyelitis virus and one or more antigens of fowl pox virus; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by avibacterium paragallinarum, avian encephalomyelitis virus and fowl pox virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.

The invention relates to fusion proteins which comprise at least one antigenic amino acid sequence fused to a carrier heterologous protein sequence, wherein the antigenic sequence comprises an epitopic sequence of a Plasmodium protein and the carrier heterologous protein sequence is a sequence that is immunogenic in humans. The proteins are useful as anti-malaria vaccines.

The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-CD28 Fab′ antibody fragment, called “FR104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of FR104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.